Sanofi/€SAN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
€SAN
Sector
Primary listing
PAR
Employees
82,878
Headquarters
Website
Sanofi Metrics
BasicAdvanced
€98B
10.95
€7.34
0.44
€3.92
4.87%
Price and volume
Market cap
€98B
Beta
0.44
52-week high
€110.88
52-week low
€76.73
Average daily volume
21K
Dividend rate
€3.92
Financial strength
Current ratio
1.274
Quick ratio
0.811
Long term debt to equity
20.951
Total debt to equity
31.709
Dividend payout ratio (TTM)
52.29%
Interest coverage (TTM)
16.91%
Profitability
EBITDA (TTM)
12,181
Gross margin (TTM)
71.34%
Net profit margin (TTM)
19.95%
Operating margin (TTM)
20.73%
Effective tax rate (TTM)
19.24%
Revenue per employee (TTM)
€550,000
Management effectiveness
Return on assets (TTM)
4.60%
Return on equity (TTM)
9.00%
Valuation
Price to earnings (TTM)
10.952
Price to revenue (TTM)
2.179
Price to book
1.4
Price to tangible book (TTM)
10.57
Price to free cash flow (TTM)
11.862
Free cash flow yield (TTM)
8.43%
Free cash flow per share (TTM)
6.78
Dividend yield (TTM)
4.87%
Forward dividend yield
4.87%
Growth
Revenue change (TTM)
15.65%
Earnings per share change (TTM)
117.96%
3-year revenue growth (CAGR)
2.85%
10-year revenue growth (CAGR)
3.35%
3-year earnings per share growth (CAGR)
11.66%
10-year earnings per share growth (CAGR)
7.23%
3-year dividend per share growth (CAGR)
5.59%
10-year dividend per share growth (CAGR)
3.24%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Sanofi exceeded expectations in the first quarter, with business operating income up 20.1% to €2.90 billion and Dupixent sales rising 20.3%. The company repurchased 72% of its €5 billion share buyback and reaffirmed full-year guidance despite global uncertainties.
The planned acquisition of Blueprint Medicines for up to $9.5 billion will broaden Sanofi’s immunology offerings beyond Dupixent by adding Ayvakit, which is already approved for systemic mastocytosis and expected to generate $2 billion in annual sales by 2030.
Sanofi’s RSV antibody Beyfortus achieved over €1.7 billion in its first full year of sales and still has considerable growth potential in the U.S. market, supporting Sanofi’s push into high-growth vaccine areas.
Dupixent accounts for nearly 40% of Sanofi’s total sales, leaving the company exposed to a major drop in revenue when its patent expires in 2031. Goldman Sachs notes Sanofi will need €11–12 billion from its wholly owned products to make up for this loss.
Sanofi’s experimental COPD drug itepekimab did not achieve its main goal in one of two Phase 3 AERIFY trials, causing Regeneron shares to drop nearly 9% and Sanofi’s U.S.-listed ADRs to fall 5%. This highlights the execution risks in Sanofi’s respiratory pipeline.
Blueprint Medicines is still unprofitable and faces rising competition from Cogent Biosciences, casting doubts over the costs to integrate and how quickly Sanofi’s up to $9.5 billion acquisition can turn profitable.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SAN) has a market cap of €98B as of September 13, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SAN) stock is 10.95 as of September 13, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SAN) stock pays dividends to shareholders. As of September 13, 2025, the dividend rate is €3.92 and the yield is 4.87%. Sanofi has a payout ratio of 52.29% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SAN) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SAN) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.